Risk of cancer in patients treated with recombinant human growth hormone in childhood
Recombinant human growth hormone (GH) has been in use for over 30 years, and its indications have gradually expanded from the classical replacement therapy in GH deficiency (GHD) to pharmacological therapy in patients with normal GH secretion. The insulin-like growth factor-I (IGF-I ) is closely GH...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Korean Society of Pediatric Endocrinology
2019-06-01
|
| Series: | Annals of Pediatric Endocrinology & Metabolism |
| Subjects: | |
| Online Access: | http://e-apem.org/upload/pdf/apem-2019-24-2-92.pdf |